250 related articles for article (PubMed ID: 12642121)
1. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease.
Mistry AR; Pedersen EW; Solomon E; Grimwade D
Blood Rev; 2003 Jun; 17(2):71-97. PubMed ID: 12642121
[TBL] [Abstract][Full Text] [Related]
2. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
3. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.
Sirulnik A; Melnick A; Zelent A; Licht JD
Best Pract Res Clin Haematol; 2003 Sep; 16(3):387-408. PubMed ID: 12935958
[TBL] [Abstract][Full Text] [Related]
5. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia.
Grimwade D; Lo Coco F
Leukemia; 2002 Oct; 16(10):1959-73. PubMed ID: 12357347
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
8. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
9. Translocations of the RARalpha gene in acute promyelocytic leukemia.
Zelent A; Guidez F; Melnick A; Waxman S; Licht JD
Oncogene; 2001 Oct; 20(49):7186-203. PubMed ID: 11704847
[TBL] [Abstract][Full Text] [Related]
10. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia.
Hummel JL; Wells RA; Dubé ID; Licht JD; Kamel-Reid S
Oncogene; 1999 Jan; 18(3):633-41. PubMed ID: 9989813
[TBL] [Abstract][Full Text] [Related]
12. Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility.
Baba SM; Pandith AA; Shah ZA; Baba RA
Clin Genet; 2019 Jan; 95(1):41-52. PubMed ID: 29700805
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
14. Current issues in the management of acute promyelocytic leukemia.
Slack JL; Rusiniak ME
Ann Hematol; 2000 May; 79(5):227-38. PubMed ID: 10870476
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
Grimwade D; Solomon E
Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
18. Identification of variant APL translocations PRKAR1A-RARα and ZBTB16-RARα (PLZF-RARα) through the MI-ONCOSEQ platform.
King D; Foucar CE; Ma V; Benitez L; Perissinotti AJ; Marini BL; Robinson D; Bhave RR; Bixby D
Cancer Genet; 2021 Nov; 258-259():57-60. PubMed ID: 34534739
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
20. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
